Diagnostic (STARD) and prognostic (REMARK) studies;Estudios de precisión diagnóstica (STARD) y pronóstica (REMARK)

Medicina Clinica

Volumn 125, Issue SUPPL. 1, 2005, Pages 49-55

  Altman, Douglas G ^a   Bossuyt, Patrick M M ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Diagnosis; Guidelines; Prognosis; REMARK; Reporting research; STARD

Indexed keywords

TUMOR MARKER;

ARTICLE; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RESEARCH; PRACTICE GUIDELINE; PROGNOSIS;

CHECKLIST; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DIAGNOSIS; HUMANS; JOURNALISM; NEOPLASMS; PERIODICALS AS TOPIC; POLICY MAKING; PROGNOSIS; PUBLISHING; RESEARCH REPORT; SOFTWARE DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 34547793566     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/s0025-7753(05)72210-7     Document Type: Article

References (27)

1. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987-91.
2. Guyatt GH, Tugwell PX, Feeny DH, Haynes RB, Drummond M. A framework for clinical evaluation of diagnostic technologies. CMAJ. 1986;134:587-94.
3. Knottnerus JA, Muris JW. Assessment of the accuracy of diagnostic tests: the cross-sectional study. J Clin Epidemiol. 2003;56:1118-28.
4. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med. 2004;140:189-202.
5. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, Van der Meulen JH, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999;282:1061-6.
6. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA. 1995;274:645-51.
7. Smidt N, Rutjes AW, Van der Windt DA, Ostelo RW, Reitsma JB, Bossuyt PM, et al. Quality of reporting of diagnostic accuracy studies. Radiology. 2005;235:347-53.
8. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Chem. 2003;49:1-6.
9. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49:7-18.
10. Smidt N, Rutjes AWS, Van der Windt DAWM, Ostelo RWJG, Reitsma JB, Bossuyt PM, et al. Does the STARD Statement improve the quality of reporting of diagnostic accuracy studies? Fifth International Congress on Peer Review and Biomedical Publication. Chicago: September 16-18 2005.
11. Schilsky RL, Taube SE. Tumor markers as clinical cancer tests are we there yet? Semin Oncol. 2002;29:211-2.
12. McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, et al. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res. 2000;6:1854-64.
13. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using «optimal» cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829-35.
14. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69:979-85.
15. Biganzoli E, Boracchi P, Marubini E. Biostatistics and tumor marker studies in breast cancer: design, analysis and interpretation issues. Int J Biol Markers. 2003;18:40-8.
16. Hall PA, Going JJ. Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology. 1999;35:489-94.
17. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002;235:10-26.
18. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer. 2003;88:1191-8.
19. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004;10:4-12.
20. Burton A, Altman DG. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer. 2004;91:4-8.
21. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22:529-36.
22. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037-57.
23. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896-900.
24. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-94.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-4.
26. Marx BE, Marx M. Prognosis of idiopathic membranous nephropathy: a methodologic meta-analysis. Kidney International. 1997;51:873-9.
27. Carson CA, Fine MJ, Smith MA, Weissfeld LA, Huber JT, Kapoor WN. Quality of published reports of the prognosis of community-acquired pneumonia. J Gen Intern Med. 1994;9:13-9.